Publications by authors named "L Sellner"
Article Synopsis
- * The trial included 28 patients and showed promising results with an overall response rate of 82%, and a complete response rate of 71%, especially in a subgroup treated with a low dosage of CAR T cells (25×10).
- * With a median follow-up of 24 months, the therapy demonstrated a 1-year event-free survival rate of 61%, while serious side effects were relatively low, indicating the potential for this approach in treating
Understanding the molecular and phenotypic heterogeneity of cancer is a prerequisite for effective treatment. For chronic lymphocytic leukemia (CLL), recurrent genetic driver events have been extensively cataloged, but this does not suffice to explain the disease's diverse course. Here, we performed RNA sequencing on 184 CLL patient samples.
View Article and Find Full Text PDFAdoptive cell therapy with NY-ESO-1-specific T cells is a promising option for the treatment of soft tissue sarcoma (STS) but achieves only transient tumor control in the majority of cases. A strategy to optimize this cell therapeutic approach might be the modulation of the expression of the cancer-testis antigen NY-ESO-1 using histone deacetylase inhibitors (HDACis). In this study, the ex vivo effect of combining NY-ESO-1-specific T cells with the clinically approved pan HDACis panobinostat or vorionstat was investigated.
View Article and Find Full Text PDFRadiotherapy (RT) efficacy can be improved by using radiosensitizers, i.e., drugs enhancing the effect of ionizing radiation (IR).
View Article and Find Full Text PDF